View More Recent Stories

Aug 8, 2024 07:41AM Sarepta Therapeutics (SRPT) PT Lowered to $200 at Piper Sandler
Aug 8, 2024 06:27AM Sarepta Therapeutics (SRPT) PT Lowered to $181 at RBC Capital
Aug 7, 2024 04:19PM Sarepta Therapeutics (SRPT) Tops Q2 EPS by 57c, provides guidance
Aug 7, 2024 10:00AM Eight defensive growth stocks to own right now
Jul 29, 2024 05:04AM RBC Capital Upgrades Sarepta Therapeutics (SRPT) to Outperform
Jul 17, 2024 08:10AM Cassava Sciences (SAVA): Remi Barbier resigns as President and CEO and from the Board of Directors
Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview
Jul 1, 2024 07:23AM Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
Jun 27, 2024 09:51AM BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
Jun 26, 2024 08:11AM Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
Jun 26, 2024 02:32AM Citi Downgrades Sarepta Therapeutics (SRPT) to Neutral
Jun 24, 2024 12:18PM Baird on Sarepta (SRPT): 'we think the regulatory progress can generate incremental optimism around the valuation'
Jun 24, 2024 10:56AM Sarepta Therapeutics (SRPT) call put ratio 2 calls to 1 put with focus on August 175 and 195 calls
Jun 24, 2024 05:33AM Sarepta Therapeutics (SRPT) PT Raised to $200 at Mizuho
Jun 21, 2024 11:13AM Sarepta Therapeutics (SRPT) option active with focus on August 175 calls as share price up 36%
Jun 21, 2024 10:50AM Sarepta Therapeutics (SRPT) PT Raised to $203 at TD Cowen
Jun 21, 2024 10:35AM Sarepta Therapeutics (SRPT) call put ratio 2.9 calls to 1 put as share price up 38% after expanded FDA approval of Elevidys for DMD
Jun 21, 2024 06:56AM Sarepta Therapeutics (SRPT) call put ratio 2.4 calls to 1 put into expanded FDA approval of Elevidys for DMD
Jun 21, 2024 05:49AM Citi Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
Jun 21, 2024 05:41AM Sarepta Therapeutics (SRPT) PT Raised to $200 at Baird, 'Best Case Label'
Jun 21, 2024 05:36AM Sarepta Therapeutics (SRPT) PT Raised to $213 at BofA Securities
Jun 21, 2024 05:25AM Goldman Sachs Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
Jun 21, 2024 04:50AM Sarepta Therapeutics (SRPT) PT Raised to $182 at RBC Capital
Jun 20, 2024 05:13PM Sarepta Therapeutics (SRPT) to resume trading at 5:35PM
Jun 20, 2024 05:02PM Sarepta Therapeutics (SRPT) Announces Expanded FDA Approval of ELEVIDYS
Jun 20, 2024 04:58PM Sarepta Therapeutics (SRPT) Receives FDA Approval of Delandistrogene in DMD
Jun 20, 2024 04:57PM Sarepta Therapeutics (SRPT) halted, news pending
Jun 20, 2024 07:23AM RBC Capital Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
Jun 18, 2024 08:43AM BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
Jun 13, 2024 10:57AM Sarepta Therapeutics gains as Pfizer failure removes overhang
Jun 13, 2024 09:44AM BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
Jun 13, 2024 07:59AM Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
Jun 12, 2024 04:45PM After-hours movers: Broadcom, Dave & Buster's, Oxford Industries, and more
Jun 12, 2024 04:33PM Sarepta Therapeutics (SRPT) Climbs After Pfizer (PFE) Study in DMD Fails
View More Recent Stories